For the second time in 16 months, Unity Biotechnology is restructuring its operations. The developer of drugs to treat diseases of aging is cutting its headcount in half to ensure its cash reserves ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Unity Biotechnology Inc. (NASDAQ: UBX) stock was ...

Management of complex quality control (QC) data is essential to insure high quality patient care and maintain regulatory compliance within clinical laboratories. Robust software solutions for ...

Unity Biotechnology Inc., a company developing therapeutics targeting age-related diseases, closed its debut on the stock market under its initial public offering price. Shares of Unity rose to $19 ...